Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Barraud, Quentin ^a   Obeid, Ibrahim ^b   Aubert, Incarnation ^a   Barrière, Gregory ^a   Contamin, Hugues ^c   McGuire, Steve ^d   Ravenscroft, Paula ^d   Porras, Gregory ^a   Tison, François ^a,b   Bezard, Erwan ^a   Ghorayeb, Imad ^a,b  

^a UMR 5287   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c Cynbiose   (France)

^d Williams House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; FLUOROGOLD; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE; DOPAMINE; DOPAMINE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CELL COUNT; CELL LABELING; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; GENE EXPRESSION; HUMAN VERSUS ANIMAL COMPARISON; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MACACA; NEUROANATOMY; NONHUMAN; PARKINSONISM; SPINAL CORD DORSAL HORN; SPINAL CORD VENTRAL HORN; ANIMAL; DIENCEPHALON; GENETICS; HISTOLOGY; METABOLISM; PRIMATE; SPINAL CORD;

PARKINSONIA; PRIMATES;

ANIMALS; DIENCEPHALON; DOPAMINE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PRIMATES; RECEPTORS, DOPAMINE; RNA, MESSENGER; SPINAL CORD;

EID: 78149463043     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013306     Document Type: Article

References (98)

1. van Os J, Kapur S (2009) Schizophrenia. Lancet 374: 635-645.
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
3. Spiga S, Lintas A, Diana M (2008) Addiction and cognitive functions. Ann N Y Acad Sci 1139: 299-306.
4. Bjorklund A, Skagerberg G (1979) Evidence for a major spinal cord projection from the diencephalic A11 dopamine cell group in the rat using transmitterspecific fluorescent retrograde tracing. Brain Res 177: 170-175.
5. Hokfelt T, Phillipson O, Goldstein M (1979) Evidence for a dopaminergic pathway in the rat descending from the A11 cell group to the spinal cord. Acta Physiol Scand 107: 393-395.
6. Skagerberg G, Lindvall O (1985) Organization of diencephalic dopamine neurones projecting to the spinal cord in the rat. Brain Res 342: 340-351.
7. Fleetwood-Walker SM, Hope PJ, Mitchell R (1988) Antinociceptive actions of descending dopaminergic tracts on cat and rat dorsal horn somatosensory neurones. J Physiol 399: 335-348.
8. Okura M, Fujiki N, Kita I, Honda K, Yoshida Y, et al. (2004) The roles of midbrain and diencephalic dopamine cell groups in the regulation of cataplexy in narcoleptic Dobermans. Neurobiol Dis 16: 274-282.
9. Barriere G, Mellen N, Cazalets JR (2004) Neuromodulation of the locomotor network by dopamine in the isolated spinal cord of newborn rat. Eur J Neurosci 19: 1325-1335.
10. Clemens S, Rye D, Hochman S (2006) Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 67: 125-130.
11. Charbit AR, Akerman S, Holland PR, Goadsby PJ (2009) Neurons of the dopaminergic/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. J Neurosci 29: 12532-12541.
12. Clemens S, Hochman S (2004) Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knockout mice. J Neurosci 24: 11337-11345.
13. Carp JS, Anderson RJ (1982) Dopamine receptor-mediated depression of spinal monosynaptic transmission. Brain Res 242: 247-254.
14. Barasi S, Ben-Sreti MM, Clatworthy AL, Duggal KN, Gonzalez JP, et al. (1987) Dopamine receptor-mediated spinal antinociception in the normal and haloperidol pretreated rat: effects of sulpiride and SCH 23390. Br J Pharmacol 90: 15-22.
15. Weil-Fugazza J, Godefroy F (1993) Dorsal and ventral dopaminergic innervation of the spinal cord: functional implications. Brain Res Bull 30: 319-324.
16. Men DS, Matsui Y (1994) Peripheral nerve stimulation increases serotonin and dopamine metabolites in rat spinal cord. Brain Res Bull 33: 625-632.
17. Gao X, Zhang YQ, Zhang LM, Wu GC (2001) Effects of intraplantar injection of carrageenan on central dopamine release. Brain Res Bull 54: 391-394.
18. Gerin C, Becquet D, Privat A (1995) Direct evidence for the link between monoaminergic descending pathways and motor activity. I. A study with microdialysis probes implanted in the ventral funiculus of the spinal cord. Brain Res 704: 191-201.
19. Gerin C, Privat A (1998) Direct evidence for the link between monoaminergic descending pathways and motor activity: II. A study with microdialysis probes implanted in the ventral horn of the spinal cord. Brain Res 794: 169-173.
20. Han P, Nakanishi ST, Tran MA, Whelan PJ (2007) Dopaminergic modulation of spinal neuronal excitability. J Neurosci 27: 13192-13204.
21. Hening W, Allen R, Earley C, Kushida C, Picchietti D, et al. (1999) The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 22: 970-999.
22. Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of Parkinsonism- chronic treatment with L-dopa. N Engl J Med 280: 337-345.
23. Bezard E, Imbert C, Gross CE (1998) Experimental models of Parkinson's disease: from the static to the dynamic. Rev Neurosci 9: 71-90.
24. Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, et al. (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57: 17-26.
25. Scholz B, Svensson M, Alm H, Skold K, Falth M, et al. (2008) Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. PLoS One 3: e1589.
26. Aubert I, Ghorayeb I, Normand E, Bloch B (2000) Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum. J Comp Neurol 418: 22-32.
27. Dearry A, Gingrich JA, Falardeau P, Fremeau RT, Jr., Bates MD, et al. (1990) Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 347: 72-76.
28. Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, et al. (1989) Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci U S A 86: 9762-9766.
29. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146-151.
30. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, et al. (1991) Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350: 614-619.
31. Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, et al. (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42: 383-390.
32. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, et al. (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinelesioned macaque model of Parkinson's disease. J Neurosci 21: 6853-6861.
33. Guigoni C, Dovero S, Aubert I, Li Q, Bioulac BH, et al. (2005) Levodopainduced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci 22: 283-287.
34. Akhavan M, Hoang TX, Havton LA (2006) Improved detection of fluorogoldlabeled neurons in long-term studies. J Neurosci Methods 152: 156-162.
35. Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, et al. (2009) Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol 219: 574-582.
36. Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R (2006) 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol Dis 23: 77-86.
37. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.
38. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
39. Holstege JC, Van Dijken H, Buijs RM, Goedknegt H, Gosens T, et al. (1996) Distribution of dopamine immunoreactivity in the rat, cat and monkey spinal cord. J Comp Neurol 376: 631-652.
40. Kitahama K, Ikemoto K, Jouvet A, Nagatsu I, Sakamoto N, et al. (1998) Aromatic L-amino acid decarboxylase- and tyrosine hydroxylase-immunohistochemistry in the adult human hypothalamus. J Chem Neuroanat 16: 43-55.
41. Westlund KN, Coulter JD (1980) Descending projections of the locus coeruleus and subcoeruleus/medial parabrachial nuclei in monkey: axonal transport studies and dopamine-beta-hydroxylase immunocytochemistry. Brain Res 2: 235-264.
42. Simonetta Moreau M, Meunier S, Vidailhet M, Pol S, Galitzky M, et al. (2002) Transmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson's disease. Brain 125: 2125-2133.
43. Liang CL, Sinton CM, Sonsalla PK, German DC (1996) Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration 5: 313-318.
44. Haber SN, Ryoo H, Cox C, Lu W (1995) Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol 362: 400-410.
45. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 122 (Pt 8): 1421-1436.
46. Bezard E, Gross CE, Brotchie JM (2003) Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 26: 215-221.
47. Bezard E, Gross CE (1998) Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol 55: 93-116.
48. Zhu H, Clemens S, Sawchuk M, Hochman S (2007) Expression and distribution of all dopamine receptor subtypes (D(1)-D(5)) in the mouse lumbar spinal cord: a real-time polymerase chain reaction and non-autoradiographic in situ hybridization study. Neuroscience 149: 885-897.
49. Zhao H, Zhu W, Pan T, Xie W, Zhang A, et al. (2007) Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J Neurosci Res 85: 1065-1076.
50. Dubois A, Savasta M, Curet O, Scatton B (1986) Autoradiographic distribution of the D1 agonist [3H]SKF 38393, in the rat brain and spinal cord. Comparison with the distribution of D2 dopamine receptors. Neuroscience 19: 125-137.
51. Whelan P, Bonnot A, O'Donovan MJ (2000) Properties of rhythmic activity generated by the isolated spinal cord of the neonatal mouse. J Neurophysiol 84: 2821-2833.
52. Jiang Z, Carlin KP, Brownstone RM (1999) An in vitro functionally mature mouse spinal cord preparation for the study of spinal motor networks. Brain Res 816: 493-499.
53. Lapointe NP, Guertin PA (2008) Synergistic effects of D1/5 and 5-HT1A/7 receptor agonists on locomotor movement induction in complete spinal cordtransected mice. J Neurophysiol 100: 160-168.
54. Lapointe NP, Rouleau P, Ung RV, Guertin PA (2009) Specific role of dopamine D1 receptors in spinal network activation and rhythmic movement induction in vertebrates. J Physiol 587: 1499-1511.
55. Kiehn O, Kjaerulff O (1996) Spatiotemporal characteristics of 5-HT and dopamine-induced rhythmic hindlimb activity in the in vitro neonatal rat. J Neurophysiol 75: 1472-1482.
56. Bourgoin S, Pohl M, Mauborgne A, Benoliel JJ, Collin E, et al. (1993) Monoaminergic control of the release of calcitonin gene-related peptide- and substance P-like materials from rat spinal cord slices. Neuropharmacology 32: 633-640.
57. Yang HW, Zhou LJ, Hu NW, Xin WJ, Liu XG (2005) Activation of spinal d1/d5 receptors induces late-phase LTP of C-fiber-evoked field potentials in rat spinal dorsal horn. J Neurophysiol 94: 961-967.
58. van Dijken H, Dijk J, Voom P, Holstege JC (1996) Localization of dopamine D2 receptor in rat spinal cord identified with immunocytochemistry and in situ hybridization. Eur J Neurosci 8: 621-628.
59. Yokoyama C, Okamura H, Nakajima T, Taguchi J, Ibata Y (1994) Autoradiographic distribution of [3H]YM-09151-2, a high-affinity and selective antagonist ligand for the dopamine D2 receptor group, in the rat brain and spinal cord. J Comp Neurol 344: 121-136.
60. Levant B, McCarson KE (2001) D(3) dopamine receptors in rat spinal cord: implications for sensory and motor function. Neurosci Lett 303: 9-12.
61. Onali P, Olianas MC, Gessa GL (1985) Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum. Mol Pharmacol 28: 138-145.
62. Tamae A, Nakatsuka T, Koga K, Kato G, Furue H, et al. (2005) Direct inhibition of substantia gelatinosa neurones in the rat spinal cord by activation of dopamine D2-like receptors. J Physiol 568: 243-253.
63. Garraway SM, Hochman S (2001) Modulatory actions of serotonin, norepinephrine, dopamine, and acetylcholine in spinal cord deep dorsal horn neurons. J Neurophysiol 86: 2183-2194.
64. Bjorklund A, Nobin A (1973) Fluorescence histochemical and microspectrofluorometric mapping of dopamine and noradrenaline cell groups in the rat diencephalon. Brain Res 51: 193-205.
65. Fuxe K (1965) Evidence For The Existence Of Monoamine Neurons In The Central Nervous System. Iv. Distribution Of Monoamine Nerve Terminals In The Central Nervous System. Acta Physiol Scand Suppl SUPPL 247: 237+.
66. Ridet JL, Sandillon F, Rajaofetra N, Geffard M, Privat A (1992) Spinal dopaminergic system of the rat: light and electron microscopic study using an antiserum against dopamine, with particular emphasis on synaptic incidence. Brain Res 598: 233-241.
67. Skagerberg G, Bjorklund A, Lindvall O, Schmidt RH (1982) Origin and termination of the diencephalo-spinal dopamine system in the rat. Brain Res Bull 9: 237-244.
68. Blessing WW, Chalmers JP (1979) Direct projection of catecholamine (presumably dopamine)-containing neurons from hypothalamus to spinal cord. Neurosci Lett 11: 35-40.
69. Qu S, Ondo WG, Zhang X, Xie WJ, Pan TH, et al. (2006) Projections of diencephalic dopamine neurons into the spinal cord in mice. Exp Brain Res 168: 152-156.
70. Mons N, Tison F, Geffard M (1989) Identification of L-dopa-dopamine and Ldopa cell bodies in the rat mesencephalic dopaminergic cell systems. Synapse 4: 99-105.
71. Meister B, Hokfelt T, Steinbusch HW, Skagerberg G, Lindvall O, et al. (1988) Do tyrosine hydroxylase-immunoreactive neurons in the ventrolateral arcuate nucleus produce dopamine or only L-dopa? J Chem Neuroanat 1: 59-64.
72. Ershov PV, Ugrumov MV, Calas A, Krieger M, Thibault J (2002) Differentiation of tyrosine hydroxylase-synthesizing and/or aromatic L-amino acid decarboxylase-synthesizing neurons in the rat mediobasal hypothalamus: quantitative double-immunofluorescence study. J Comp Neurol 446: 114-122.
73. Karasawa N, Hayashi M, Yamada K, Nagatsu I, Iwasa M, et al. (2007) Tyrosine hydroxylase (TH)- and aromatic-L-amino acid decarboxylase (AADC)-immunoreactive neurons of the common marmoset (Callithrix jacchus) brain: an immunohistochemical analysis. Acta Histochem Cytochem 40: 83-92.
74. Weihe E, Depboylu C, Schutz B, Schafer MK, Eiden LE (2006) Three types of tyrosine hydroxylase-positive CNS neurons distinguished by dopa decarboxylase and VMAT2 co-expression. Cell Mol Neurobiol 26: 659-678.
75. Tison F, Mons N, Geffard M, Henry P (1990) Immunohistochemistry of endogenous L-DOPA in the rat posterior hypothalamus. Histochemistry 93: 655-660.
76. McEwen ML, Van Hartesveldt C, Stehouwer DJ (1997) L-DOPA and quipazine elicit air-stepping in neonatal rats with spinal cord transections. Behav Neurosci 111: 825-833.
77. Baker LL, Chandler SH, Goldberg LJ (1984) L-dopa-induced locomotor-like activity in ankle flexor and extensor nerves of chronic and acute spinal cats. Exp Neurol 86: 515-526.
78. Tison F, Mons N, Geffard M, Henry P (1991) The metabolism of exogenous Ldopa in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain. J Neural Transm Park Dis Dement Sect 3: 27-39.
79. Karasawa N, Arai R, Isomura G, Nagatsu T, Nagatsu I (1995) Chemical features of monoaminergic and non-monoaminergic neurons in the brain of laboratory shrew (Suncus murinus) are changed by systemic administration of monoamine precursors. Neurosci Res 24: 67-74.
80. Ugrumov MV (2009) Non-dopaminergic neurons partly expressing dopaminergic phenotype: distribution in the brain, development and functional significance. J Chem Neuroanat 38: 241-256.
81. Bjorklund A, Dunnett SB (2007) Dopamine neuron systems in the brain: an update. Trends Neurosci 30: 194-202.
82. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, et al. (1999) Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409: 38-56.
83. Lorang D, Amara SG, Simerly RB (1994) Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci 14: 4903-4914.
84. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonisminducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A 82: 2173-2177.
85. Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, et al. (1999) Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 155: 268-273.
86. Pifl C, Schingnitz G, Hornykiewicz O (1991) Effect of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44: 591-605.
87. Cuenca N, Herrero MT, Angulo A, de Juan E, Martinez-Navarrete GC, et al. (2005) Morphological impairments in retinal neurons of the scotopic visual pathway in a monkey model of Parkinson's disease. J Comp Neurol 493: 261-273.
88. Emborg ME, Moirano J, Schafernak KT, Moirano M, Evans M, et al. (2006) Basal ganglia lesions after MPTP administration in rhesus monkeys. Neurobiol Dis 23: 281-289.
89. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311: 464-467.
90. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, et al. (2003) Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4: 101-119.
91. Bara-Jimenez W, Aksu M, Graham B, Sato S, Hallett M (2000) Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex. Neurology 54: 1609-1616.
92. Stiasny-Kolster K, Magerl W, Oertel WH, Moller JC, Treede RD (2004) Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain 127: 773-782.
93. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, et al. (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci U S A 93: 1945-1949.
94. Chen PK, Fuh JL, Chen SP, Wang SJ. Association between restless legs syndrome and migraine. J Neurol Neurosurg Psychiatry 81: 524-528.
95. Rhode AM, Hosing VG, Happe S, Biehl K, Young P, et al. (2007) Comorbidity of migraine and restless legs syndrome-a case-control study. Cephalalgia 27: 1255-1260.
96. d'Onofrio F, Bussone G, Cologno D, Petretta V, Buzzi MG, et al. (2008) Restless legs syndrome and primary headaches: a clinical study. Neurol Sci 29 Suppl 1: S169-172.
97. Ondo WG, He Y, Rajasekaran S, Le WD (2000) Clinical correlates of 6- hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord 15: 154-158.
98. Schilling C, Schredl M, Strobl P, Deuschle M. Restless legs syndrome: Evidence for nocturnal hypothalamic-pituitary-adrenal system activation. Mov Disord 25: 1047-1052.